WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Intuitive wins a CE mark for adult cardiac surgery with da Vinci 5 FDA drafts surgical robot testing expectations and leaves autonomy out of scope Marani Health clears the M•care system for fetal and maternal monitoring at home FDA books December 2 and 3 for a workshop on robot autonomy and remote teleoperation Glytec wins Breakthrough designation for insulin dosing software in newborns Perfuze bench study puts Millipede88 first-pass success at 88 percent in MCA models Precision Neuroscience raises $250M Series D and takes total funding to $430M FDA calls BD's kit correction Class I over recalled saline ampules from a supplier FDA early alert flags a loose cable that reboots React Health VOCSN ventilators Intuitive wins a CE mark for adult cardiac surgery with da Vinci 5 FDA drafts surgical robot testing expectations and leaves autonomy out of scope Marani Health clears the M•care system for fetal and maternal monitoring at home FDA books December 2 and 3 for a workshop on robot autonomy and remote teleoperation Glytec wins Breakthrough designation for insulin dosing software in newborns Perfuze bench study puts Millipede88 first-pass success at 88 percent in MCA models Precision Neuroscience raises $250M Series D and takes total funding to $430M FDA calls BD's kit correction Class I over recalled saline ampules from a supplier FDA early alert flags a loose cable that reboots React Health VOCSN ventilators

Commercial

Microbot Medical puts Liberty in 12 sales territories and targets positive gross margin in 2027

MedDevice Startups Staff · 2 days ago · 2 min read · Via Microbot Medical (GlobeNewswire)

Microbot Medical said it will have Liberty in 12 US sales territories by the end of 2026. The company laid the plan out at an analyst meeting in New York on September 24 and published it the next day.

Liberty is a single-use, remotely operated robot for peripheral endovascular work, cleared by FDA in September 2025. Microbot signed a first California customer and is adding accounts in North Carolina. It hired three area sales managers and a regional sales director. Value analysis committee reviews at the target health systems run four to six months.

A second manufacturing line is going in, and the company expects positive gross margins in 2027. It put CE marking in late Q4 2026 or early Q1 2027 and called distribution talks in Asia and the Middle East advanced.

Twelve territories is a small footprint for a robot cleared a year ago, and the four to six month committee cycle explains most of it. Clearance set the start date, hospital purchasing sets the slope.

Questions & Answers

How many sales territories will Microbot Medical's Liberty cover in 2026?

Microbot Medical said on September 25, 2026 that it will have Liberty in 12 US sales territories by the end of the year. It has signed its first California customer and is adding accounts in North Carolina.

When was the Microbot Medical Liberty system cleared by FDA?

FDA cleared the Liberty endovascular robotic system in September 2025 for peripheral endovascular procedures. Liberty is a single-use, remotely operated robot controlled from outside the radiation field.

When does Microbot Medical expect positive gross margins on Liberty?

Microbot Medical expects positive gross margins in 2027, helped by a second manufacturing line and process changes. It also expects CE marking in late Q4 2026 or early Q1 2027.

← Back to Startups